ADHD community seeks DEA action in med shortages

"When you have a controlled substance problem, the DEA has to be involved in fixing it," says Ruth Hughes, CEO at Children and Adults with Attention Deficit/Hyperactivity Disorder. Drugs like Adderall and Ritalin, which have controlled-substance APIs among the 400 basic substances and derivatives regulated by the U.S. Drug Enforcement Agency, present an additional hurdle when it comes to resolving shortages. "It is not sufficient to say it is an industry problem. We need to figure out how to build more flexibility into the system." Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.